HGS CEO hails from TAP
Former TAP Pharmaceuticals President Thomas Watkins joins Human Genome Sciences as CEO. Watkins worked for Abbott-affiliated companies for almost 20 years, including six years serving as president of the Takeda/Abbott joint venture; his term as president was limited by the joint venture agreement (1"The Pink Sheet" Sept. 6, 2004, p. 8). Watkins replaces former HGS CEO William Haseltine, PhD, who also retired as chairman; Argeris Karabelis, PhD, became chairman Oct. 17...
You may also be interested in...
Former TAP VP-sales Alan MacKenzie will become president of the company effective Sept. 1
The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.
Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.